A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML

Abstract. The proportion of patients with acute myeloid leukemia (AML) cured is increased by administering high-dose cytarabine (HiDAC). It remains uncertain whether to administer HiDAC as induction or consolidation, and whether ≥1 cycle of HiDAC is required. Our retrospective study of 416 adult AML...

Full description

Bibliographic Details
Main Authors:	Anthony P. Schwarer, Jason Butler, Kathryn Jackson, Ashanka Beligaswatte, Louisa Martin, Glen Kennedy, Zantomio Daniela, Ian Lewis, Devendra Hiwase, Joel Wight, Simon He, Andrew Grigg, Kirk Morris, Peter Mollee, Paula Marlton
Format:	Article
Language:	English
Published:	Wiley 2018-12-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000158

Similar Items

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: Shahriari Ahmadi A, et al.
Published: (2004-08-01)

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: A Shahriari Ahmadi, et al.
Published: (2004-03-01)

PB1838: TOXICITY AND OUTCOME OF HIGH DOSE CYTARABINE (18 G/M2) FOR AML CONSOLIDATION.
by: L. Lopes, et al.
Published: (2022-06-01)

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial
by: Jun Li, et al.
Published: (2022-12-01)

High-dose cytarabine monotherapy is superior to standard-dose cytarabine- based multiagent sequential treatment cycle for consolidation treatment in adult (14-59 years) AML patients according to European Leukemia Net 2022 risk stratification
by: Xiaoyu Wang, et al.
Published: (2023-01-01)

How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?
by: Ing Soo Tiong, et al.
Published: (2024-03-01)

P443: IMPACT OF PHARMACOGENETIC VARIANTS ON CYTARABINE AND ANTHRACYCLINE EFFECT ON OUTCOMES IN ADULT AML PATIENTS
by: Z. Pravdic, et al.
Published: (2022-06-01)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
by: Xiao-Hua Luo, et al.
Published: (2023-08-01)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
by: Emmanuel Gyan, et al.
Published: (2022-06-01)

P543: TARGETING SAMHD1 WITH HYDROXYUREA IN FIRST-LINE CYTARABINE-BASED THERAPY OF NEWLY DIAGNOSED ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE HEAT-AML TRIAL
by: M. Jädersten, et al.
Published: (2022-06-01)

Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.
by: Jing Wang, et al.
Published: (2013-01-01)

PB2363: R-MPV FOLLOWED BY CONSOLIDATION REDUCED-DOSE WHOLE-BRAIN RADIOTHERAPY AND CYTARABINE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: REAL WORLD DATA
by: Maha EL Amani, et al.
Published: (2023-08-01)

Effect of Granulocyte Colony-Stimulating Factor on the Development of Spermatogenesis in the Adulthood of Juvenile AML Mice Model Treated with Cytarabine
by: Bara’ah Khaleel, et al.
Published: (2023-07-01)

Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia
by: Kenneth F. Bradstock, et al.
Published: (2016-12-01)

Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis
by: Barbara Tomic, et al.
Published: (2022-07-01)

Disrupting the LC3 Interaction Region (LIR) Binding of Selective Autophagy Receptors Sensitizes AML Cell Lines to Cytarabine
by: Mateusz Putyrski, et al.
Published: (2020-03-01)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
by: Qingguo Liu, et al.
Published: (2020-07-01)

Effects of Combinatory In Vitro Treatment with Immune Checkpoint Inhibitors and Cytarabine on the Anti-Cancer Immune Microenvironment in De Novo AML Patients
by: Łukasz Bołkun, et al.
Published: (2024-01-01)

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
by: Katie Fooks, et al.
Published: (2022-12-01)

TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
by: Yoko Tabe, et al.
Published: (2013-01-01)

Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
by: Chengzhi Xie, et al.
Published: (2013-01-01)

Cytarabine-Induced Encephalitis
by: Christine Lenfant, et al.
Published: (2021-09-01)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
by: Jingyi Zhang, et al.
Published: (2022-04-01)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
by: Juan Miguel Bergua Burgues, et al.
Published: (2023-08-01)

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia
by: M.C. Azevedo, et al.
Published: (2015-02-01)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
by: L. Minarik, et al.
Published: (2022-06-01)

Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study
by: Jing Liu, et al.
Published: (2022-01-01)

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML
by: Paola Minetto, et al.
Published: (2023-08-01)

Advances in therapeutic options for newly diagnosed, high-risk AML patients
by: Kimberley Doucette, et al.
Published: (2021-05-01)

The Efficacy and Safety of Cytarabine on Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
by: Xiaohong Zheng, et al.
Published: (2020-07-01)

Integrative single‐cell expression and functional studies unravels a sensitization to cytarabine‐based chemotherapy through HIF pathway inhibition in AML leukemia stem cells
by: Talia Velasco‐Hernandez, et al.
Published: (2024-02-01)

Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase‐3‐mediated cleavage of the AML1‐ETO oncoprotein
by: Jiang Cao, et al.
Published: (2016-11-01)

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
by: Tremblay G, et al.
Published: (2019-09-01)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Xiao Han, et al.
Published: (2023-08-01)

P543: CONSECUTIVE DAY DOSING OF HIGH-DOSE CYTARABINE CONSOLIDATION OVER 3 DAYS IS FEASIBLE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA
by: Rithin Nedumannil, et al.
Published: (2023-08-01)

Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
by: Jun-Feng Zhu, et al.
Published: (2022-10-01)

P525: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ENTOSPLETINIB ADDED TO INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN NEWLY DIAGNOSED NPM1-MUTATED AML
by: J. C. Byrd, et al.
Published: (2022-06-01)

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
by: Iyer SG, et al.
Published: (2022-08-01)

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
by: Haorui Shen, et al.
Published: (2023-08-01)

Clinical characteristics of delayed generalized erythema associated with cytarabine
by: He Jiang, et al.
Published: (2024-03-01)